Trusted by the world’s leading institutions

clients clients clients clients clients clients clients clients clients clients clients
Newswise: New analysis platform shines light on utilities’ solar energy future
Release date: 13-May-2024 11:05 AM EDT
New analysis platform shines light on utilities’ solar energy future
Oak Ridge National Laboratory

Researchers at the Department of Energy’s Oak Ridge National Laboratory, in collaboration with three other national labs, have developed a free online platform to help utilities understand how solar energy projects will affect the operation of their power systems. This capability can increase utilities’ confidence in expanding their solar portfolios, protecting reliable delivery of electricity while supporting U.S. efforts to slow climate change.

Newswise: New Research and Treatment Advances From Yale Cancer Center to be Presented at the World’s Largest Cancer Research Conference
Release date: 13-May-2024 11:05 AM EDT
New Research and Treatment Advances From Yale Cancer Center to be Presented at the World’s Largest Cancer Research Conference
Yale Cancer Center/Smilow Cancer Hospital

Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill. This year's meeting, themed “The Art and Science of Cancer Care: From Comfort to Cure” will include over 200 sessions.

Newswise: Natural biosurfactants: the future of eco-friendly meat preservation
Release date: 13-May-2024 11:05 AM EDT
Natural biosurfactants: the future of eco-friendly meat preservation
Chinese Academy of Sciences

Recently, exciting new paper unveils the potential of biosurfactants—natural compounds produced by microbes—to significantly improve the preservation of meat products. This innovative approach could replace synthetic chemicals, enhancing food safety and quality.

Newswise: Argonne’s Aurora supercomputer breaks exascale barrier
Released: 13-May-2024 10:45 AM EDT
Argonne’s Aurora supercomputer breaks exascale barrier
Argonne National Laboratory

Argonne’s Aurora system has officially entered the exascale era with its latest submission to the Top500 list of the world’s most powerful supercomputers.

Released: 13-May-2024 10:05 AM EDT
When consumers would prefer a chatbot over a person
Ohio State University

Actually, sometimes consumers don’t want to talk to a real person when they’re shopping online, a new study suggests. In fact, what they really want is a chatbot that makes it clear that it is not human at all.

Released: 13-May-2024 10:00 AM EDT
Plant virus treatment shows promise in fighting metastatic cancers in mice
University of California San Diego

An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego.

Released: 13-May-2024 9:50 AM EDT
Endocrine Society and European Society of Endocrinology publish joint guideline on glucocorticoid-induced adrenal insufficiency
Endocrine Society

The joint guideline is designed to help clinicians manage patients who have, or are at risk of developing, glucocorticoid-induced adrenal insufficiency. At least 1% of the global population uses chronic glucocorticoid therapy as anti-inflammatory or immune-suppressive agents.

13-May-2024 9:30 AM EDT
New Treatment in Pipeline for Patients with Hypertrophic Cardiomyopathy
Lahey Hospital & Medical Center

One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the walls of the left ventricle to become thick and stiff. In about 70 percent of cases, patients with HCM experience obstruction to blood flow, which increases pressures in the heart and can lead to chest pain, shortness of breath and reduced exercise capacity. While invasive interventions can restore selected patients’ quality of life, pharmacologic therapies that are safe, well-tolerated and that reliably improve how patients feel and function remain an unmet need for patients with obstructive HCM. Now, a phase 3 trial has shown that a cardiac myosin inhibitor called aficamten enhances exercise capacity in patients with HCM and leads to significant relief in the burden of limiting symptoms, improving the quality of patients' lives

Released: 13-May-2024 9:05 AM EDT
Negotiations for a Global Pandemic Agreement Extended
Wildlife Conservation Society

Member States of the World Health Organization (WHO) were due to converge on text for a global pandemic agreement during their ninth and final negotiating session in March; however, insufficient progress was made in those two weeks, in terms of finding consensus.


close
2.22756